RARE - Ultragenyx Pharmaceutical Inc.

QQQ $ 426.27 $ 6.25 (1.49 %)

DIA $ 385.03 $ 2.65 (0.69 %)

SPY $ 505.65 $ 5.93 (1.19 %)

TLT $ 89.02 $ 0.03 (0.03 %)

GLD $ 214.96 $ -0.53 (-0.25 %)

Previous Close

$ 45.11

Open

$ 43.82

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 43.82 - $ 45.54

52 Week Range

$ 31.52 - $ 54.98

Volume

836,684

Average Volume

Market Cap

3.32B

Beta (5Y Monthly)

$ 0.99

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-21-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-05-2023	03-31-2023	10-Q
5	02-17-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	07-28-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	02-15-2022	12-31-2021	10-K
10	11-02-2021	09-30-2021	10-Q
11	08-03-2021	06-30-2021	10-Q
12	05-05-2021	03-31-2021	10-Q
13	02-12-2021	12-31-2020	10-K
14	10-27-2020	09-30-2020	10-Q
15	07-31-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	02-14-2020	12-31-2019	10-K
18	11-06-2019	09-30-2019	10-Q
19	08-02-2019	06-30-2019	10-Q
20	05-07-2019	03-31-2019	10-Q
21	02-20-2019	12-31-2018	10-K
22	11-06-2018	09-30-2018	10-Q
23	08-03-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	02-21-2018	12-31-2017	10-K
26	11-03-2017	09-30-2017	10-Q
27	07-28-2017	06-30-2017	10-Q
28	05-05-2017	03-31-2017	10-Q
29	02-17-2017	12-31-2016	10-K
30	11-08-2016	09-30-2016	10-Q
31	08-09-2016	06-30-2016	10-Q
32	05-10-2016	03-31-2016	10-Q
33	02-26-2016	12-31-2015	10-K
34	11-10-2015	09-30-2015	10-Q
35	08-14-2015	06-30-2015	10-Q
36	05-12-2015	03-31-2015	10-Q
37	03-27-2015	12-31-2014	10-K
38	11-10-2014	09-30-2014	10-Q
39	08-11-2014	06-30-2014	10-Q
40	05-12-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Forecasting The Future: 11 Analyst Project...
04/22/2024 12:00:56

RBC Capital Initiates Coverage On Ultragen...
04/22/2024 09:42:30

RBC Capital analyst Luca Issi initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform rating and ann...

Wedbush Reiterates Neutral on Ultragenyx P...
04/17/2024 17:20:21

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $48 price target.

Wedbush Reiterates Neutral on Ultragenyx P...
04/16/2024 14:20:52

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $48 price target.

sp-500-down-over-1-us-retail-sales-increase-07-in-march

S&P 500 Down Over 1%; US Retail Sales Incr...
04/15/2024 18:30:37

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0...

why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Ultragenyx Pharmaceutical Shares Are T...
04/15/2024 18:11:35

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

Crude Oil Down 1%; Charles Schwab Sales To...
04/15/2024 16:02:33

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow tra...

rare-disease-focused-ultragenyx-pharmaceutical-stock-falls-on-serious-adverse-events-in-eaarly-genetic-disorder-study

Rare Disease-Focused-Ultragenyx Pharmaceut...
04/15/2024 14:40:19

New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding nat...

marinus-pharmaceuticals-neumora-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Marinus Pharmaceuticals, Neumora Therapeut...
04/15/2024 12:19:30

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Ultragenyx Reveal New Data From Phase 1/2 ...
04/15/2024 11:07:24

Patients in Expansion Cohorts A & B treated with a set dose and regimen of GTX-102 showed rapid and clinically meaningful i...

Ultragenyx Announces Update To Conference ...
04/12/2024 20:23:58

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link belowNOVATO, Calif., April 12, 202...

Expert Outlook: Ultragenyx Pharmaceutical ...
04/05/2024 16:00:58

Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:21:15

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

Analyst Scoreboard: 8 Ratings For Ultragen...
03/18/2024 13:00:13

JP Morgan Maintains Overweight on Ultragen...
03/18/2024 11:57:32

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price targe...

Cantor Fitzgerald Maintains Overweight on ...
02/27/2024 14:27:16

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and announces $...

Canaccord Genuity Maintains Buy on Ultrage...
02/21/2024 14:14:41

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price tar...

Wedbush Maintains Neutral on Ultragenyx Ph...
02/16/2024 13:55:37

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and raises the price target fro...

Recap: Ultragenyx Pharmaceutical Q4 Earnings
02/15/2024 21:05:26

Ultragenyx Reaffirms 2024 Total Revenue Ou...
02/15/2024 21:05:20